医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Targeted Medical Pharma Finalizes Exclusive Agreement for Distribution in China

2016年01月14日 AM03:00
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Targeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product licensing agreement with Healthy Focus Limited, a Hong Kong based company that specializes in distributing healthcare products throughout China.

The Agreement grants Healthy Focus an exclusive three-year renewable license for the marketing and sale of Theramine®, Percura and Trepadone® in Hong Kong and China. Under the terms of the Agreement, Healthy Focus is responsible for registering all products in China, an initial licensing fee, as well as maintaining annual minimum purchase orders of $500,000 for the first two years, and $1 million in the third year.

“We are excited to partner with Healthy Focus Limited to introduce our products to the Chinese Market,” said Kim Giffoni, Chief Executive Officer at Targeted Medical Pharma. “The execution of this agreement represents a significant expansion of international sales of our proprietary line of health products, and positions us for sustainable growth over the next three years.”

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and the dietary supplement for sinus and immune support, Clearwayz. The products are sold directly to physicians, pharmacies, patients and hospitals in the United States and abroad.

Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160113005336/en/

CONTACT

Company:
Targeted
Medical Pharma

Marcus Charuvastra, 310-474-9809
marcusch@tmedpharma.com
or
Investor:
Targeted
Medical Pharma

William B. Horne, 310-474-9809
whorne@tmedpharma.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Murata Invests in MEMS Sensor Manufacturing in Finland
  • Evaluate Ltd: Small Drug Developers Continue to Hold All the Cards, While Young Device Makers Suffer from a Shrinking Pool of Buyers
  • ABLIC Inc. Launches the S-85M0A Series of Ultra-High Efficiency Step-Down Switching Regulators in the Industry’s Most Compact(*) Size
  • Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation
  • 和铂医药与科伦博泰就PD-L1抗体A167开展全球战略合作